[Is Etolip suitable for treatment of various types of hyperlipoproteinemias?].
Etolip is the first Czechoslovak hypolipidaemic preparation produced in the Pharmaceutical Research Institute in Modra. As to the chemical structure it is ethophylline clofibrate. It was administered to 39 manual workers with hyperlipoproteinaemia type IIa, IIb, III, IV and V-500 mg/day, i.e. 2-0-2 capsules. The mean age of the patients varied round 43 +/- 6.1 years. They were subdivided into study possible, comparing Lipanthyl and Etolip. Despite the fact that the subjects did not adhere to a strict diet and occasionally consumed 50-100 g alcohol, Etolip (E) reduced the triacylglycerol concentration (TG) in serum for a period of one month after administration on average by 28% (p less than 0.01) in workers with hyperlipoproteinaemia (HL) type IIb, III, IV and V. In group A it is reduced from 2.8 +/- 1.0 mmol/l to 1.7 +/- 0.5 mmol/l and in group B from 2.4 +/- 1.0 mmol/l to 2.0 +/- 1.0 mmol/l. The total cholesterol concentration (CH) in serum declines after E on average in both groups by 11.4% (p less than 0.01) in the mentioned types of HL, whereby in subjects with HL type IIa and III it is practically unchanged. The apolipoprotein B concentration declines in serum of groups A and B from 185.6 +/- 37.8 to 137.5 +/- 44.2 mg/dl and from 144.9 +/- 27.9 to 113.3 +/- 23.6 mg/dl. After one month treatment with this drug the blood sugar level, and serum creatinine concentration does not rise, the haemogram and the uric acid concentration do not change. E raises the AST and ALT concentration to double the initial value which is still at the borderline of normal values.
Kollár
J
J
Ustav experimentálnej medicíny Lekárskej fakulty P. J. Safárika Kosice.
Rozdobud'ková
V
V
Koprovicová
J
J
Rajnová
E
E
Seiler
J
J
D000328:Adult; D002994:Clofibrate / Q000627:therapeutic use*; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008875:Middle Aged
D008055:Lipids; D002994:Clofibrate
Je vhodný Etolip k liecbe niektorých hyperlipoproteinémií?